Association of bone pain at metastatic hormone-sensitive prostate cancer diagnosis with survival: secondary analysis of SWOG-1216

The presence of bone pain is significantly associated with worse overall survival among patients with castration-resistant prostate cancer. A secondary analysis of the phase 3 SWOG-1216 trial, at 248 centers in the USA, investigated the association of baseline bone pain with survival outcomes among patients with metastatic hormone-sensitive prostate cancer (mHSPC). Baseline bone pain was reported by 25.1% of patients in the analysis. Baseline bone pain was associated with significantly shorter progression-free survival and overall survival. The authors conclude that these data suggest prioritizing patients with bone pain at diagnosis for enrollment in clinical trials, and that the inclusion of bone pain in prognostic models of mHSPC may be warranted.